U.S. Residents
References
1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood. 2000;96:3343-3356.
2. Galton DA. Myleran in chronic myeloid leukaemia; results of treatment. Lancet. 1953;264:208-213.
3. Sawyers CL. Chronic myeloid leukaemia. N Engl J Med. 1999;340:1330-1340.
4. Glivec Summary of Product Characteristics [SMPC]. Basel, Switzerland: Novartis Pharma AG; 2006.
5. Druker BJ, Guilhot F, O'Brien S, Larson RA, on behalf of the IRIS. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukaemia in chronic phase (CML-CP): the 5-year update from the IRIS study [abstract]. J Clin Oncol. 2006;24:338s. Abstract 6506. Oral presentation.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med. 2006;355:2408-2417.
7. Baccarani M, Guilhot F, Larson RA, G. OBS, Druker B, IRIS obot. on behalf of the IRIS Study Group. Outcomes by cytogenetic and molecular response at 12 and 18 months of imatinib in patients with newly diagnosed chronic myeloid leukaemia (CML) in chronic phase (CP) in the IRIS trial [abstract]. Blood. 2006;108:606a. Abstract 2138.
8. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukaemia. Recommendations from an expert panel on behalf of the European LeukaemiaNet. Blood. 2006;108:1809-1820.
9. Hoffbrand AV, Pettit JE, Moss PAH. Essential Haematology. 4th ed. Oxford, UK: Blackwell Science; 2001.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
11. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
12. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1:31-36.
13. Greenlee RT, Hill-Harmon MB , Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
14. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2001.Accessed July 15, 2005.
15. Cortes J. Natural history and staging of chronic myelogenous leukaemia. Haematol Oncol Clin North Am. 2004;18:569-584.
16. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukaemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536-1543.
17. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukaemia: update on biology and treatment. Oncology (Williston Park).1999;13:169-180; discussion 181, 184.
18. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukaemia with interferon-alpha and chemotherapy. Haematol Oncol Clin North Am. 1998;12:31-80.
19. Spiers AS. Clinical manifestations of chronic granulocytic leukaemia. Semin Oncol. 1995;22:380-395.
20. Silver RT. Chronic myeloid leukaemia. Haematol Oncol Clin North Am. 2003;17:1159-1173, vi-vii.
21. Quintas-Cardama A, Cortes JE. Chronic myeloid leukaemia: diagnosis and treatment. Mayo Clin Proc. 2006;81:973-988.
22. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukaemia: a review. Am J Med. 1996;100:555-570.
23. Osarogiagbon UR, McGlave PB. Chronic myelogenous leukaemia. Curr Opin Haematol. 1999;6:241-246.
24. Goldman JM, Melo JV. Chronic myeloid leukaemia--advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
25. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172-183.
26. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukaemia. Blood. 1984;63:789-799.
27. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858.
28. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukaemia. N Engl J Med. 2003;349:1423-1432.
29. Simonsson B. Beneficial effects of cytogenetic and molecular response on long-term outcomes in patients with newly diagnosed chronic myeloid leukaemia in chronic phase treated with imatinib: Update from the IRIS study [abstract]. Blood. 2005;106:52a. Abstract 166.
30. Hasford J, Rosti G, Baccarani M, et al. The European Leukaemia Net CML Registry--objectives, achievements and first results [abstract]. Blood. 2006;108:279b. Abstract 4781.
31. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukaemia after cytogenetic response to interferon-alpha therapy. The Leukaemia Service. Ann Intern Med. 1995;122:254-261.
32. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukaemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074-3081.
33. Kantarjian H, Sawyers C, Hochhaus A, et al. Haematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med. 2002;346:645-652.
34. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
35. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM. Available at: http://www.nccn.org/index.asp. Accessed July 19, 2006.
36. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukaemia in chronic phase. Leukaemia. 2003;17:2401-2409.
37. Paschka P, Muller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukaemia. 2003;17:1687-1694.
38. Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic phase chronic myeloid leukaemia. Blood. 2004;103:2284-2290.
39. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukaemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
40. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukaemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82:398-407.
41. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukaemia. French Chronic Myeloid Leukaemia Study Group. N Engl J Med. 1997;337:223-229.
42. Ozer H, George SL, Schiffer CA , et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukaemia: effect on remission duration and survival: Cancer and Leukaemia Group B study 8583. Blood. 1993;82:2975-2984.
43. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukaemia. The German CML Study Group. Blood. 1994;84:4064-4077.
44. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukaemia in chronic phase. Blood. 1995;86:906-916.
45. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukaemia. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Blood. 1998;92:1541-1548.
46. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukaemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992;10:772-778.
47. Sacchi S, Kantarjian HM, O'Brien S, et al. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukaemia. Leukaemia. 1997;11:1610-1616.
48. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukaemia: developed for the American Society of Haematology. Blood. 1999;94:1517-1536.
49. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukaemia: strategies to avoid and overcome resistance. Leukaemia. 2004;18:1321-1331.
50. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukaemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood. 2000;95:62-66.
51. Passweg JR, Rowlings PA, Horowitz MM. Related donor bone marrow transplantation for chronic myelogenous leukaemia. Haematol Oncol Clin North Am. 1998;12:81-92.
52. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
53. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol. 2004;125:613-620.
54. Goldman JM. Chronic myeloid leukaemia. Curr Opin Haematol. 1997;4:277-285.
55. Hehlmann R, Hochhaus A, Berger U, Reiter A. Current trends in the management of chronic myelogenous leukaemia. Ann Haematol. 2000;79:345-354.
56. van Rhee F, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukaemia in chronic phase: a report from the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20:553-560.
57. Petersdorf E, Anasetti C, Servida P, Martin P, Hansen J. Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukaemia. Haematol Oncol Clin North Am. 1998;12:107-121.
58. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukaemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981-2990.
59. Clift RA, Radich J, Appelbaum FR, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukaemia. Blood. 1999;94:3960-3962.
60. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukaemia: long-term results. Chronic Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1993;12:509-516.
61. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996;17(Suppl 3):S5-S6.
62. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukaemia: 9 years' experience of the national marrow donor program. Blood. 2000;95:2219-2225.
63. Peggs K, Mackinnon S. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukaemia. N Engl J Med. 2003;348:1048-1050.
64. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
65. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. Apr 24 2007 [Epub ahead of print].
66. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
67. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukaemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380-394.
68. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
69. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938-1942.
70. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62:4236-4243.
71. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
72. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692-1703.
73. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127-3132.
74. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440-2448.
75. Champagne MA, Fu C, Chang M, et al. Imatinib in children with newly diagnosed chronic phase chronic myelogenous leukaemia (CP CML): AAML0123 COG study [abstract]. Blood. 2006;108:607a. Abstract 2140.
76. Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients (pts) receiving imatinib therapy [abstract]. Blood. 2006;108:609a. Abstract 2146.
77. Legros L, Breuil V, Farrari P, Tests J, Cassuto J-L. Hypophosphatemia observed in chronic myeloid leukaemia patients treated with imatinib mesylate (Gleevec®) is related to digestive side-effects [abstract]. Blood. 2006;108:274b. Abstract 4765.
78. Kantarjian HM, Larson RA, Guilhot F, G. OBS, Druker BJ, group obotIs. on behalf of the IRIS study group. Declining rates of adverse events (AEs), rare occurrence of serious AEs (SAEs), and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukaemia (CML) in chronic phase (CP) initially treated with imatinib (IM) in the International Randomized Study of Interferon vs STI571 (IRIS) [abstract]. Blood. 2006;108:605a. Abstract 2136.
79. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia. Blood. 2004;103:2873-2878.
80. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukaemia: historical comparison between two phase 3 trials. Blood. 2006;108:1478-1484.
81. Kantarjian HM, Sawyers C, Hochhaus A, et al. Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukaemia (CML) post interferon-A (IFN) refractoriness/Intolerance [abstract]. Blood. 2006;108:130a. Abstract 428.